Metagenomi Therapeutics, Inc. (MGX)
Nasdaq · Healthcare · Biotechnology
$1.04+1.96%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $39.3M
- 52-week range
- $1.01 – $3.95
- 52-week change
- −65.42%
- EPS (trailing)
- −$2.49
- Analyst rating
- 1.4 Strong buy
Fiscal year to Dec 2025
- Revenue
- $25.2M (−51.79%)
- Net income
- −$87.9M
- Operating margin
- −380.9%
- Diluted EPS
- −$2.36
- Free cash flow
- −$89.5M
From the company’s annual report on SEC EDGAR.
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Headquarters: EmeryVille, United States · 113 employees · metagenomi.co